Skip to main content
. 2022 Aug 2;12:816198. doi: 10.3389/fonc.2022.816198

Figure 3.

Figure 3

Survival profiles. The PFS (A) and OS (B) in HCC patients receiving camrelizumab plus TACE. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PFS, progression-free survival; OS, overall survival; NR, not reached.